Laura Kleiman, PhD

Laura Kleiman, PhD, is the founder and CEO of Reboot Rx, a nonprofit advancing affordable cancer treatments by repurposing generic drugs. Many patients could benefit from these medicines, but once patents expire, the traditional drug development model is not structured to support further research, evidence dissemination, or FDA review for other uses. After losing her mother to cancer and seeing this gap firsthand, Laura launched Reboot Rx to help close it.

Laura leads Reboot Rx’s vision, partnerships, and strategy to translate AI-driven insights into real-world clinical impact. Under her leadership, Reboot Rx has pioneered the use of AI to systematically identify repurposed generic drugs with strong potential for near-term clinical adoption. The organization has launched collaborations with the Veterans Health Administration and the SWOG Cancer Research Network, secured early support from leading philanthropic funders including Arnold Ventures, Pershing Square Foundation, and Lyda Hill Philanthropies, and advanced policy innovation to create viable nonprofit pathways for generic drug repurposing.

Laura is a Draper Richards Kaplan Foundation Entrepreneur and a Henri Termeer Fellow. Her work has been recognized by 40 Under 40 in Cancer, Extraordinary Women Advancing Healthcare, and the MassNextGen Initiative, and featured in Forbes, The Boston Globe, and Inside Philanthropy. She brings more than 20 years of experience spanning cancer research, data science, and healthcare innovation.

Prior to founding Reboot Rx, Laura served as a scientific research director at the Dana-Farber Cancer Institute. She earned her PhD in computational and systems biology from MIT and was an American Cancer Society postdoctoral fellow at Massachusetts General Hospital and Harvard Medical School.